Brief: Hoth Therapeutics Secures European Authorization In Spain
05/05/2026 22:45
May 5 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS SECURES EUROPEAN AUTHORIZATION IN SPAIN FOR HT-001 PHASE 2A TRIAL AS INTERIM DATA SHOW STRONG EFFICACY IN CANCER PATIENTS HOTH THERAPEUTICS INC - HT-001 PHASE 2A INTERIM DATA SHOW PRIMARY EFFICACY ENDPOINT ACHIEVED BY WEEK 6 HOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED MEANINGFUL REDUCTIONS IN PAIN AND ITCHING IN HT-001 TRIAL HOTH THERAPEUTICS INC - NO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATION OF EGFR INHIBITOR THERAPY HOTH THERAPEUTICS INC - NO TREATMENT-LIMITING ADVERSE EVENTS OBSERVED IN HT-001 PHASE 2A TRIAL Source text: ID:nPn76tRXka Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology